Tilray is a global leader in medical cannabis research, cultivation, processing and distribution. We aspire to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.
Growers / Distributors

Tilray News

23 Mar

What Tilray Thinks About The 'Farming Business' And Why The Company May Need To Raise More Capital Soon

Although many companies are starting to gear up to release financial results for the first quarter, investors have nevertheless waited patiently for Tilray ( TLRY ) to release its results for the fourth...

22 Mar

Where the Democratic Candidates Stand on Cannabis

Though marijuana legalization may not be the top overall campaign issue heading into 2020, it remains an important part of many candidates' platforms.

22 Mar

Cannabis Stocks ACB, CRON, APHA, TLRY Trending Lower Today

Cannabis Stocks ACB, CRON, APHA, TLRY Trending Lower TodayCannabis sector trending lower The overall cannabis sector took a hit today amid the broader market’s declines. The volatility index (VIX) jumped...

22 Mar

Tilray Is Still Too High

Earlier this week, Canadian cannabis firm Tilray ( TLRY ) reported its fourth quarter results . While the company beat analyst estimates on the top line, the bottom line saw a much larger than expected...

21 Mar

Vape Distributor Greenlane Holdings Files S-1 Form, Plans NASDAQ IPO

Florida-based Greenlane Holdings, a distributor of premium vaporization products and consumption accessories, said it applied to list its class A common stock on the NASDAQ Global Market under the ticker...

21 Mar

CRON, ACB, CGC, APHA, and Other Cannabis Stocks Trend Lower

CRON, ACB, CGC, APHA, and Other Cannabis Stocks Trend LowerCannabis sectorThe overall cannabis sector was trading almost flat to negative in the first half of March 21. The Horizons Marijuana Life Science...

21 Mar

Investing in Marijuana, Without Tilray

Down huge from its highs, Tilray is far from a steal, but there’s still plenty green to be made in this space.

21 Mar

Canopy Growth: What’s Its Strategy in the United States?

Canopy Growth Sets Its Eyes on the US Market(Continued from Prior Part)Hemp’s potential Previously in this series, we discuss some of the product research from ebbu—Canopy Growth’s (WEED) (CGC) US subsidiary....

21 Mar

Innovative Industrial Properties: Analysts’ View in March

March Update: Analysts’ Ratings for TLRY, IIPR, and SPRWF(Continued from Prior Part)Innovative Industrial PropertiesLast week, Innovative Industrial Properties (IIPR) reported its earnings. The company...

21 Mar

Canopy Growth Sets Its Eyes on the US Market

Canopy Growth Sets Its Eyes on the US MarketNew acquisitionOn March 20, Canopy Growth (WEED) (CGC) announced that it signed a multiyear extraction agreement with HollyWeed. The company is back in the news...

Load more

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

A proud pioneer, we are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents.

Tilray's experience is unmatched worldwide. Our team professionals on the ground in 7 countries serves thousands of patients around the globe. Our flagship cultivation facility is among the most advanced in the world.

Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extracts. All of our products are produced with meticulous care to ensure the highest quality, consistency and purity for our patients.

We are committed to scientific research that leads to an improved quality of life for patients in a time frame that matters. We partner with leading hospitals and universities to advance the clinical applications of cannabinoids.

Tilray takes tremendous pride in our customer service, patient outreach, and physician interaction. We recognize the importance of tracking potential adverse events as well as therapeutic benefits in order to ensure the safety of our patients.



Governor Howard Dean
Michael Steele
The Honourable Lloyd...
Joschka Fischer
Jaime Gama
The Honourable Alexa...
Rt Hon Sir Donald Mc...
María Lorena Gutiérr...
James O’Brien
Dr. Lorna Marsden
Brendan Kennedy
Chief Executive Officer
Mark Castaneda
Chief Financial Officer
Woody Pastorius
Chief Revenue Officer
Adine Fabiani-Carter
Chief Marketing Officer
Catherine Jacobson
Regulatory & Medical Affairs
Christy Zhou
General Counsel, Tilray Canada
Josh Eades
VP, Chief Science Officer
Scott Krompocker
VP, Operations, Tilray Nanaimo
Philippe Lucas
VP, Patient Research and Access
John Andonoff
VP, Sales & Marketing
Marla Luther
Director of Business Development, Europe
Steven Yoo
Director of Corporate Investments
Sean Carney
Director of Business Development & Government Rela...
Françoise Lévesque
Master Horticulturist
Tom McGaugh
Director of Finance

Participation in events

$ 67.16
Share volume:
160.951 K
Total value:
12.625 M
Market cap:
6.436 B